Evidence map›Paper›PMID 25569376›Full record

ArticleCytokine2015

Invariant natural killer T cells generated from human adult hematopoietic stem-progenitor cells are poly-functional.

Wenji Sun, Yi Wang, James E East, Amy S Kimball, Katherine Tkaczuk, Susan Kesmodel, Scott E Strome, Tonya J Webb

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cytokine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wenji SunDepartment of Microbiology and Immunology, University of Maryland School of Medicine, and the Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, United States.
Yi WangDepartment of Regenerative Medicine, School of Pharmaceutical Sciences, Jilin University, Changchun, PR China.
James E EastDepartment of Microbiology and Immunology, University of Maryland School of Medicine, and the Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, United States.
Amy S KimballDepartment of Medicine, University of Maryland School of Medicine, and the Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, United States.
Katherine TkaczukDepartment of Medicine, University of Maryland School of Medicine, and the Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, United States.
Susan KesmodelDepartment of Surgery, University of Maryland School of Medicine, and the Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, United States.
Scott E StromeDepartment of Otorhinolaryngology-Head and Neck Surgery, University of Maryland School of Medicine, and the Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, United States.
Tonya J WebbDepartment of Microbiology and Immunology, University of Maryland School of Medicine, and the Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, United States. Electronic address: twebb@som.umaryland.edu.

Funding

Training Grant in Cancer BiologyT32CA154274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Toni M Antalis, CURT I CIVIN · 2011 to 2026
$6.8M
aAPC-Mediated NKT cell Modulation to Enhance Cancer ImmunotherapyK01CA131487 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI WEBB, TONYA J. · 2008 to 2012
$584k
Restoring NKT cell function: a novel immunotherapeutic strategy for Breast CancerR21CA162273 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI WEBB, TONYA J. · 2011 to 2012
$367k
Altered cellular bioenergetics influences NKT cell mediated responses to LymphomaR21CA162277 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI WEBB, TONYA J. · 2011 to 2012
$359k
NCI NIH HHS K01 CA131487NCI NIH HHS K01CA131487NCI NIH HHS R21 CA162273NCI NIH HHS R21 CA162277NCI NIH HHS T32 CA154274
6 · The paper itself

Abstract

Invariant natural killer T (iNKT) cells constitute an important subset of T cells that can both directly and indirectly mediate anti-tumor immunity. However, cancer patients have a reduction in both iNKT cell number and function, and these deficits limit the potential clinical application of iNKT cells for cancer therapy. To overcome the problem of limited iNKT cell numbers, we investigated whether iNKT cells can be generated in vitro from bone marrow-derived adult hematopoietic stem-progenitor cells (HSPC). Our data demonstrate that co-culture of HSPC with OP9-DL1 stromal cells, results in a functional CD3(+) T cell population. These T cells can be further differentiated into iNKT cells by secondary culture with CD1d-Ig-based artificial antigen-presenting cells (aAPC). Importantly, these in vitro-generated iNKT cells are functional, as demonstrated by their ability to proliferate and secrete IFN-γ and GM-CSF following stimulation.

Indexed as

Lymphocyte ActivationAdultAntigen-Presenting CellsAntigens, CD1dCell DifferentiationCoculture TechniquesFlow CytometryGranulocyte-Macrophage Colony-Stimulating FactorHematopoietic Stem CellsHumansInterferon-gammaNatural Killer T-CellsStromal CellsAntigens, CD1dGranulocyte-Macrophage Colony-Stimulating FactorInterferon-gammaAdoptive immunotherapyCD1dNKT cellsStem cells

Identifiers

PMID25569376
PMCPMC4329102

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.